Special Episode: Participating in MS Research with Chiquita Shepard-Knight and Earl Sneed episode artwork

EPISODE · Nov 20, 2025 · 16 MIN

Special Episode: Participating in MS Research with Chiquita Shepard-Knight and Earl Sneed

from RealTalk MS · host Jon Strum with Chiquita Shepard-Knight and Earl Sneed

Welcome to a RealTalk MS special series on MS clinical trials. This special series is made possible through a generous grant from Sanofi. In today's episode, you'll meet two participants from the TEAMS Study, a research study at the University of Illinois Chicago's UI Health, in conjunction with the University of Alabama Birmingham School of Public Health. TEAAMS is an acronym for Targeted Exercise for African-Americans with Multiple Sclerosis. And the study's research team analyzed the effects of a remotely delivered, racially tailored exercise training program among African Americans with MS living in low-income areas of the Southeastern United States, including Alabama, Georgia, Mississippi, North Carolina, South Carolina, Louisiana, Arkansas, and Tennessee. This is a part of the country that doesn't have many primary care or MS clinics that provide full exercise and rehabilitation services for patients with MS. The TEAMMS study consists of two 16-week exercise programs, completed 3 days per week at home. One exercise program combines aerobic and resistance training, while the other focuses on stretching and flexibility. Study participants were randomly assigned to one of the two programs, and all of the materials to complete each program, like yoga mats, resistance bands, and training manuals, were provided. And every study participant receives a $90 gift card in compensation for completing the program. The study's research team hypothesizes that completing the TEAAMS program would improve walking, reduce symptoms of fatigue, anxiety, depression, and pain, and enhance quality of life. This special episode of RealTalk MS is made possible by a generous grant from Sanofi. Sanofi has two ongoing Phase 3 clinical trials in MS studying Frexalimab, an investigational second-generation anti-CD40 ligand monoclonal antibody. If you are interested in learning more about these clinical trials, please visit SanofiStudies.com SHARE THIS EPISODE OF REALTALK MS Just copy this link & paste it into your text or email: https://realtalkms.com/ct3 ADD YOUR VOICE TO THE CONVERSATION I've always thought about the RealTalk MS podcast as a conversation. And this is your opportunity to join the conversation by sharing your feedback, questions, and suggestions for topics that we can discuss in future podcast episodes. Please shoot me an email or call the RealTalk MS Listener Hotline and share your thoughts! Email: [email protected] Phone: (310) 526-2283 And don't forget to join us in the RealTalk MS Facebook group! Privacy Policy

NOW PLAYING

Special Episode: Participating in MS Research with Chiquita Shepard-Knight and Earl Sneed

0:00 16:27

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Frequently Asked Questions

How long is this episode of RealTalk MS?

This episode is 16 minutes long.

When was this RealTalk MS episode published?

This episode was published on November 20, 2025.

What is this episode about?

Welcome to a RealTalk MS special series on MS clinical trials. This special series is made possible through a generous grant from Sanofi. In today's episode, you'll meet two participants from the TEAMS Study, a research study at the University of...

Can I download this RealTalk MS episode?

Yes, you can download this episode by clicking the download button on the episode player, or subscribe to the podcast in your preferred podcast app for automatic downloads.
URL copied to clipboard!